177 related articles for article (PubMed ID: 22267468)
1. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients.
van der Beek MT; Marijt EW; Vossen AC; van der Blij-de Brouwer CS; Wolterbeek R; Halkes CJ; Claas EC; Kroes AC
Antivir Ther; 2012; 17(1):45-51. PubMed ID: 22267468
[TBL] [Abstract][Full Text] [Related]
2. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
3. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
4. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
[TBL] [Abstract][Full Text] [Related]
5. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy.
Buyck HC; Griffiths PD; Emery VC
J Clin Virol; 2010 Sep; 49(1):32-6. PubMed ID: 20667769
[TBL] [Abstract][Full Text] [Related]
6. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
[TBL] [Abstract][Full Text] [Related]
8. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis.
Roblin X; Pillet S; Oussalah A; Berthelot P; Del Tedesco E; Phelip JM; Chambonnière ML; Garraud O; Peyrin-Biroulet L; Pozzetto B
Am J Gastroenterol; 2011 Nov; 106(11):2001-8. PubMed ID: 21788989
[TBL] [Abstract][Full Text] [Related]
10. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
11. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
[TBL] [Abstract][Full Text] [Related]
12. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
13. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
[TBL] [Abstract][Full Text] [Related]
15. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
[TBL] [Abstract][Full Text] [Related]
17. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
18. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
19. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
